Call Options

8 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.21 - $2.63 $8,840 - $10,520
4,000 New
4,000 $9,000
Q1 2024

May 15, 2024

SELL
$2.18 - $3.58 $2,834 - $4,654
-1,300 Reduced 13.54%
8,300 $24,000
Q4 2023

Feb 14, 2024

SELL
$1.71 - $2.57 $8,208 - $12,336
-4,800 Reduced 33.33%
9,600 $22,000
Q3 2023

Nov 14, 2023

SELL
$2.51 - $3.55 $47,940 - $67,805
-19,100 Reduced 57.01%
14,400 $37,000
Q2 2023

Aug 14, 2023

BUY
$2.12 - $4.47 $3,816 - $8,046
1,800 Added 5.68%
33,500 $119,000
Q1 2023

May 15, 2023

SELL
$1.93 - $13.1 $74,691 - $506,970
-38,700 Reduced 54.97%
31,700 $69,000
Q4 2022

Feb 14, 2023

SELL
$5.88 - $12.03 $95,844 - $196,089
-16,300 Reduced 18.8%
70,400 $846,000
Q3 2022

Nov 14, 2022

SELL
$4.6 - $9.91 $1,380 - $2,973
-300 Reduced 0.34%
86,700 $562,000

Others Institutions Holding ORMP

About ORAMED PHARMACEUTICALS INC.


  • Ticker ORMP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,827,100
  • Market Cap $92.4M
  • Description
  • Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for th...
More about ORMP
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.